^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
AmoyDx® HRD Focus Panel

Type:
Laboratory Developed Test
Related tests:
Evidence Level:
Sensitive: C3 – Early Trials

[HRD-Ovarian Cancer-olaparib]

Source:
Title:
The correlation of homologous recombination deficiency status with and Olaparib efficacy in Chinese ovarian cancer patients.
Published date:
05/26/2022
Excerpt:
A significant PFS benefit was seen in HRD-positive patients compared with HRD-negative ones (P = 0.0017) or in the first-line maintenance treated population (P = 0.0068).
DOI:
10.1200/JCO.2022.40.16_suppl.e17556
Evidence Level:
Sensitive: C3 – Early Trials

[HRD-Ovarian Cancer-niraparib]

Title:
The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China
Published date:
05/17/2021
Excerpt:
Twenty-two patients all received niraparib at a bolus of 200 mg/d. Fifty percent of patients with high-grade serous ovarian cancer are HRD-positive....two patients achieved partial response (PR) and one patient achieved stable disease (SD), yielding objective response rate (ORR) of 33.3%...
DOI:
10.1186/s13048-021-00803-2